SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Mathieu Schmitt, Benjamin Dehay, Erwan Bezard, F. Javier Garcia-Ladona, Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line, Synapse, 2016, 70, 3
  2. 2
    Cornelius J. H. M. Klemann, Gerard J. M. Martens, Geert Poelmans, Jasper E. Visser, Validity of the MPTP-Treated Mouse as a Model for Parkinson’s Disease, Molecular Neurobiology, 2016, 53, 3, 1625

    CrossRef

  3. 3
    Kelly M. Lohr, Kristen A. Stout, Amy R. Dunn, Minzheng Wang, Ali Salahpour, Thomas S. Guillot, Gary W. Miller, Increased Vesicular Monoamine Transporter 2 (VMAT2;Slc18a2) Protects against Methamphetamine Toxicity, ACS Chemical Neuroscience, 2015, 6, 5, 790

    CrossRef

  4. 4
    Eugene V. Mosharov, Anders Borgkvist, David Sulzer, Presynaptic effects of levodopa and their possible role in dyskinesia, Movement Disorders, 2015, 30, 1
  5. 5
    Vernic Jackson-Lewis, Deranda Lester, Elena Kozina, Serge Przedborski, Richard J. Smeyne, Movement Disorders, 2015,

    CrossRef

  6. 6
    Kelly M. Lohr, Alison I. Bernstein, Kristen A. Stout, Amy R. Dunn, Carlos R. Lazo, Shawn P. Alter, Minzheng Wang, Yingjie Li, Xueliang Fan, Ellen J. Hess, Hong Yi, Laura M. Vecchio, David S. Goldstein, Thomas S. Guillot, Ali Salahpour, Gary W. Miller, Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo, Proceedings of the National Academy of Sciences, 2014, 111, 27, 9977

    CrossRef

  7. 7
    Alison I. Bernstein, Kristen A. Stout, Gary W. Miller, The vesicular monoamine transporter 2: An underexplored pharmacological target, Neurochemistry International, 2014, 73, 89

    CrossRef

  8. 8
    Erin M. G. Allen, Virginia R. Florang, Laurie L. Davenport, Yunden Jinsmaa, Jonathan A. Doorn, Cellular Localization of Dieldrin and Structure–Activity Relationship of Dieldrin Analogues in Dopaminergic Cells, Chemical Research in Toxicology, 2013, 26, 7, 1043

    CrossRef

  9. 9
    John D. Elsworth, D. Eugene Redmond, Robert H. Roth, Coordinated expression of dopamine transporter and vesicular monoamine transporter in the primate striatum during development, Synapse, 2013, 67, 9
  10. 10
    David S. Goldstein, Patti Sullivan, Courtney Holmes, Gary W. Miller, Shawn Alter, Randy Strong, Deborah C. Mash, Irwin J. Kopin, Yehonatan Sharabi, Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease, Journal of Neurochemistry, 2013, 126, 5
  11. 11
    Sebastián Rodríguez, Tsuyoshi Ito, Xi Jun He, Kazuyuki Uchida, Hiroyuki Nakayama, Resistance of the golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-neurotoxicity is not only related with low levels of cerebral monoamine oxidase-B, Experimental and Toxicologic Pathology, 2013, 65, 1-2, 127

    CrossRef

  12. 12
    Shawn P. Alter, Gina M. Lenzi, Alison I. Bernstein, Gary W. Miller, Vesicular Integrity in Parkinson’s Disease, Current Neurology and Neuroscience Reports, 2013, 13, 7

    CrossRef

  13. 13
    Patricia Muñoz, Irmgard Paris, Laurie H. Sanders, J. Timothy Greenamyre, Juan Segura-Aguilar, Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012, 1822, 7, 1125

    CrossRef

  14. 14
    B.A. Morrow, R.H. Roth, D.E. Redmond, S. Diano, J.D. Elsworth, Susceptibility to a parkinsonian toxin varies during primate development, Experimental Neurology, 2012, 235, 1, 273

    CrossRef

  15. 15
    Zhe Wang, Faiza Ferdousy, Hakeem Lawal, Zhinong Huang, J. Gavin Daigle, Iyare Izevbaye, Olugbenga Doherty, Jerrad Thomas, Dean G Stathakis, Janis M. O’Donnell, Catecholamines up integrates dopamine synthesis and synaptic trafficking, Journal of Neurochemistry, 2011, 119, 6
  16. 16
    Jelena Mijatovic, Marjo Piltonen, Paolo Alberton, Pekka T. Männistö, Mart Saarma, T. Petteri Piepponen, Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals, Neurobiology of Aging, 2011, 32, 8, 1486

    CrossRef

  17. 17
    Junchao Tong, Isabelle Boileau, Yoshiaki Furukawa, Li-Jan Chang, Alan A Wilson, Sylvain Houle, Stephen J Kish, Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies, Journal of Cerebral Blood Flow & Metabolism, 2011, 31, 10, 2065

    CrossRef

  18. 18
    David S. Goldstein, Courtney Holmes, Irwin J. Kopin, Yehonatan Sharabi, Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases, Journal of Clinical Investigation, 2011, 121, 8, 3320

    CrossRef

  19. 19
    Xiu-Min Li, Chang-Liang Xu, Ji-Min Deng, Lu-Fan Li, Shi-Ping Ma, Rong Qu, Protective effect of Zhen-Wu-Tang (ZWT) through keeping DA stable and VMAT 2/DAT mRNA in balance in rats with striatal lesions induced by MPTP, Journal of Ethnopharmacology, 2011, 134, 3, 768

    CrossRef

  20. 20
    Zhicheng Lin, Juan J. Canales, Thröstur Björgvinsson, Morgane Thomsen, Hong Qu, Qing-Rong Liu, Gonzalo E. Torres, S. Barak Caine, The Brain as a Drug Target, 2011,

    CrossRef

  21. 21
    Kimberly M. Gerecke, Yun Jiao, Amar Pani, Vishwajeeth Pagala, Richard J. Smeyne, Exercise protects against MPTP-induced neurotoxicity in mice, Brain Research, 2010, 1341, 72

    CrossRef

  22. You have free access to this content22
    Maria Gabriela Sánchez, Mélanie Bourque, Marc Morissette, Thérèse Di Paolo, Steroids-Dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders, CNS Neuroscience & Therapeutics, 2010, 16, 3
  23. 23
    Domingo Afonso-Oramas, Ignacio Cruz-Muros, Pedro Barroso-Chinea, Diego Álvarez de la Rosa, Javier Castro-Hernández, Josmar Salas-Hernández, Teresa Giráldez, Tomás González-Hernández, The dopamine transporter is differentially regulated after dopaminergic lesion, Neurobiology of Disease, 2010, 40, 3, 518

    CrossRef

  24. 24
    Ichiro Sora, BingJin Li, Moe Igari, F. Scott Hall, Kazutaka Ikeda, Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs, Annals of the New York Academy of Sciences, 2010, 1187, 1
  25. 25
    Eugene V Mosharov, David Sulzer, Convergence of multiple hits that could underlie Parkinson’s disease, Future Neurology, 2009, 4, 5, 525

    CrossRef

  26. 26
    Anne-Marie Duchemin, Hailing Zhang, Norton H. Neff, Maria Hadjiconstantinou, Increased expression of VMAT2 in dopaminergic neurons during nicotine withdrawal, Neuroscience Letters, 2009, 467, 2, 182

    CrossRef

  27. 27
    Thomas S. Guillot, Gary W. Miller, Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons, Molecular Neurobiology, 2009, 39, 2, 149

    CrossRef

  28. 28
    Stefan Schildknecht, Dominik Pöltl, Daniel M. Nagel, Florian Matt, Diana Scholz, Julie Lotharius, Nathalie Schmieg, Alberto Salvo-Vargas, Marcel Leist, Requirement of a dopaminergic neuronal phenotype for toxicity of low concentrations of 1-methyl-4-phenylpyridinium to human cells, Toxicology and Applied Pharmacology, 2009, 241, 1, 23

    CrossRef

  29. 29
    W. Michael Caudle, Rebecca E. Colebrooke, Piers C. Emson, Gary W. Miller, Altered vesicular dopamine storage in Parkinson's disease: a premature demise, Trends in Neurosciences, 2008, 31, 6, 303

    CrossRef

  30. 30
    Ignacio Cruz-Muros, Domingo Afonso-Oramas, Pedro Abreu, Manuel Rodríguez, M. Carmen González, Tomás González-Hernández, Deglycosylation and subcellular redistribution of VMAT2 in the mesostriatal system during normal aging, Neurobiology of Aging, 2008, 29, 11, 1702

    CrossRef

  31. 31
    Jason R. Richardson, W. Michael Caudle, Min Zheng Wang, E. Danielle Dean, Kurt D. Pennell, Gary W. Miller, Developmental heptachlor exposure increases susceptibility of dopamine neurons to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)in a gender-specific manner, NeuroToxicology, 2008, 29, 5, 855

    CrossRef

  32. 32
    Jun Tang Guo, An Qi Chen, Qi Kong, Hua Zhu, Chun Mei Ma, Chuan Qin, Inhibition of Vesicular Monoamine Transporter-2 Activity in α-Synuclein Stably Transfected SH-SY5Y Cells, Cellular and Molecular Neurobiology, 2008, 28, 1, 35

    CrossRef

  33. 33
    Thomas S. Guillot, Kennie R. Shepherd, Jason R. Richardson, Min Z. Wang, Yingjie Li, Piers C. Emson, Gary W. Miller, Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis, Journal of Neurochemistry, 2008, 106, 5
  34. 34
    Ming-Kai Chen, Hiroto Kuwabara, Yun Zhou, Robert J. Adams, James R. Brašić, Jennifer L. McGlothan, Tatyana Verina, Neal C. Burton, Mohab Alexander, Anil Kumar, Dean F. Wong, Tomás R. Guilarte, VMAT2 and dopamine neuron loss in a primate model of Parkinson’s disease, Journal of Neurochemistry, 2008, 105, 1
  35. 35
    Faneng Sun, Vellareddy Anantharam, Huajun Jin, Danhui Zhang, Arthi Kanthasamy, Anumantha G. Kanthasamy, Parkinson's Disease, 2008,

    CrossRef

  36. 36
    Hideko Yamamoto, Etsuko Kamegaya, Yoko Hagino, Kazuhide Imai, Akihiro Fujikawa, Kohei Tamura, Tomoyuki Enokiya, Toshifumi Yamamoto, Takao Takeshima, Hisashi Koga, George R. Uhl, Kazutaka Ikeda, Ichiro Sora, Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture, Neurochemistry International, 2007, 51, 2-4, 237

    CrossRef

  37. 37
    D. Marazziti, S. Mandillo, C. Di Pietro, E. Golini, R. Matteoni, G. P. Tocchini-Valentini, GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs, Proceedings of the National Academy of Sciences, 2007, 104, 23, 9846

    CrossRef

  38. 38
    Setsu Fukushima, Haowei Shen, Harumi Hata, Arihisa Ohara, Kayo Ohmi, Kazutaka Ikeda, Yohtaro Numachi, Hideaki Kobayashi, F. Scott Hall, George R. Uhl, Ichiro Sora, Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice, Psychopharmacology, 2007, 193, 1, 55

    CrossRef

  39. 39
    Amy B. Manning-BoĞ, J. William Langston, Model fusion: The next phase in developing animal models for parkinson’s disease, Neurotoxicity Research, 2007, 11, 3-4, 219

    CrossRef

  40. 40
    K.S. Rommelfanger, D. Weinshenker, Norepinephrine: The redheaded stepchild of Parkinson's disease, Biochemical Pharmacology, 2007, 74, 2, 177

    CrossRef

  41. 41
    S. Karakaya, M. Kipp, C. Beyer, Oestrogen Regulates the Expression and Function of Dopamine Transporters in Astrocytes of the Nigrostriatal System, Journal of Neuroendocrinology, 2007, 19, 9
  42. 42
    Justin D. Boyd, Haeman Jang, Kennie R. Shepherd, Ciaran Faherty, Sally Slack, Yun Jiao, Richard J. Smeyne, Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta, Brain Research, 2007, 1175, 107

    CrossRef

  43. 43
    Robert H. Edwards, The Neurotransmitter Cycle and Quantal Size, Neuron, 2007, 55, 6, 835

    CrossRef

  44. 44
    Sandra Vergo, Jens Leander Johansen, Marcel Leist, Julie Lotharius, Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels, Brain Research, 2007, 1185, 18

    CrossRef

  45. 45
    ROBERT T. FREMEAU, ROBERT H. EDWARDS, Protein Trafficking in Neurons, 2007,

    CrossRef

  46. 46
    Renee M. Miller, Howard J. Federoff, Microarrays in Parkinson’s disease: A systematic approach, NeuroRX, 2006, 3, 3, 319

    CrossRef

  47. 47
    Renee M. Miller, Howard J. Federoff, Microarrays in Parkinson’s disease: A systematic approach, NeuroRX, 2006, 3, 3, 319

    CrossRef

  48. 48
    Luisa Iacovelli, Federica Fulceri, Antonio De Blasi, Ferdinando Nicoletti, Stefano Ruggieri, Francesco Fornai, The neurotoxicity of amphetamines: Bridging drugs of abuse and neurodegenerative disorders, Experimental Neurology, 2006, 201, 1, 24

    CrossRef

  49. 49
    Guangrong Zheng, Linda P. Dwoskin, Peter A. Crooks, Vesicular monoamine transporter 2: Role as a novel target for drug development, The AAPS Journal, 2006, 8, 4, E682

    CrossRef

  50. 50
    Won Yong Lee, Eun Ah Lee, Mi Young Jeon, Ho Young Kang, Yong Gu Park, Vesicular monoamine transporter-2 and aromatic l-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent l-3,4-dihydroxyphenylalanine administration, Experimental Neurology, 2006, 197, 1, 215

    CrossRef

  51. 51
    Ciaran J. Faherty, Kennie Raviie Shepherd, Anna Herasimtschuk, Richard J. Smeyne, Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism, Molecular Brain Research, 2005, 134, 1, 170

    CrossRef

  52. 52
    Francesco Fornai, Paola Soldani, Gloria Lazzeri, Adolfo Bandettini di Poggio, Francesca Biagioni, Federica Fulceri, Serena Batini, Stefano Ruggieri, Antonio Paparelli, Neuronal inclusions in degenerative disorders, Brain Research Bulletin, 2005, 65, 4, 275

    CrossRef

  53. 53
    W. Michael Caudle, Jason R. Richardson, Minzheng Wang, Gary W. Miller, Perinatal Heptachlor Exposure Increases Expression of Presynaptic Dopaminergic Markers in Mouse Striatum, NeuroToxicology, 2005, 26, 4, 721

    CrossRef

  54. 54
    Carol X.-Q. Chen, Steven Y. Huang, Limei Zhang, Yong-Jian Liu, Synaptophysin enhances the neuroprotection of VMAT2 in MPP+-induced toxicity in MN9D cells, Neurobiology of Disease, 2005, 19, 3, 419

    CrossRef

  55. 55
    Richard Jay Smeyne, Vernice Jackson-Lewis, The MPTP model of Parkinson's disease, Molecular Brain Research, 2005, 134, 1, 57

    CrossRef

  56. 56
    Amy K. Jassen, Jeffrey M. Brown, Helen N. Panas, Gregory M. Miller, Danqing Xiao, Bertha K. Madras, Variants of the primate vesicular monoamine transporter-2, Molecular Brain Research, 2005, 139, 2, 251

    CrossRef

  57. 57
    Stephen B. Dunnett, Dopamine, 2005,

    CrossRef

  58. 58
    VERNICE JACKSON-LEWIS, RICHARD JAY SMEYNE, Animal Models of Movement Disorders, 2005,

    CrossRef

  59. 59
    Tomás González-Hernández, Pedro Barroso-Chinea, Ignacio de la Cruz Muros, María del Mar Pérez-Delgado, Manuel Rodríguez, Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons, Journal of Comparative Neurology, 2004, 479, 2
  60. 60
    Chang-Lin Liang, Omar Nelson, Umar Yazdani, Parichehr Pasbakhsh, Dwight C. German, Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: Human midbrain dopamine neurons, Journal of Comparative Neurology, 2004, 473, 1
  61. 61
    Stanley Fahn, David Sulzer, Neurodegeneration and neuroprotection in Parkinson disease, NeuroRX, 2004, 1, 1, 139

    CrossRef

  62. 62
    Stanley Fahn, David Sulzer, Neurodegeneration and neuroprotection in Parkinson disease, NeuroRX, 2004, 1, 1, 139

    CrossRef

  63. 63
    Carine Cleren, Bertrand Naudin, Jean Costentin, Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons, Brain Research, 2003, 989, 2, 187

    CrossRef

  64. 64
    Simone M. Smits, Tiia Ponnio, Orla M. Conneely, J. Peter H. Burbach, Marten P. Smidt, Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons, European Journal of Neuroscience, 2003, 18, 7
  65. 65
    Marten P. Smidt, Simone M. Smits, J.Peter H. Burbach, Molecular mechanisms underlying midbrain dopamine neuron development and function, European Journal of Pharmacology, 2003, 480, 1-3, 75

    CrossRef

  66. 66
    Jyoti Patel, Katrin A. Mooslehner, Pok Man Chan, Piers C. Emson, Jonathan A. Stamford, Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice, Journal of Neurochemistry, 2003, 85, 4
  67. 67
    Raul Gainetdinov, Laura Bohn, Marc Caron, Dopamine Receptors and Transporters, 2003,

    CrossRef

  68. 68
    Ryan R Metzger, Jeffrey M Brown, Verónica Sandoval, Kristi S Rau, Mohamed A Elwan, Gary W Miller, Glen R Hanson, Annette E Fleckenstein, Inhibitory effect of reserpine on dopamine transporter function, European Journal of Pharmacology, 2002, 456, 1-3, 39

    CrossRef

  69. 69
    Maria E. Reveron, Katerina V. Savelieva, Jennifer L. Tillerson, Alison L. McCormack, Donato A. Di Monte, Gary W. Miller, l-DOPA Does Not Cause Neurotoxicity in VMAT2 Heterozygote Knockout Mice, NeuroToxicology, 2002, 23, 4-5, 611

    CrossRef

  70. 70
    A. Ekue, J.-F. Boulanger, M. Morissette, T. Di Paolo, Lack of Effect of Testosterone and Dihydrotestosterone Compared to 17β-Oestradiol in 1-Methyl-4-Phenyl-1,2,3,6, Tetrahydropyridine-Mice, Journal of Neuroendocrinology, 2002, 14, 9
  71. 71
    Toshio Obata, Role of hydroxyl radical formation in neurotoxicity as revealed by in vivo free radical trapping, Toxicology Letters, 2002, 132, 2, 83

    CrossRef

  72. 72
    I.N Krasnova, B Ladenheim, S Jayanthi, J Oyler, T.H Moran, M.A Huestis, J.L Cadet, Amphetamine-induced toxicity in dopamine terminals in CD-1 and C57BL/6J mice: complex roles for oxygen-based species and temperature regulation, Neuroscience, 2001, 107, 2, 265

    CrossRef

  73. 73
    Katja Hofele, Marco Sedelis, Georg W. Auburger, Sarah Morgan, Joseph P. Huston, Rainer K.W. Schwarting, Evidence for a Dissociation between MPTP Toxicity and Tyrosinase Activity Based on Congenic Mouse Strain Susceptibility, Experimental Neurology, 2001, 168, 1, 116

    CrossRef

  74. 74
    Colin Davidson, Andrew J. Gow, Tong H. Lee, Everett H. Ellinwood, Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment, Brain Research Reviews, 2001, 36, 1, 1

    CrossRef

  75. 75
    Bing Yi Wu, Rong Yu Liu, Ka Lun So, Albert C.H. Yu, Multi-lipofection efficiently transfected genes into astrocytes in primary culture, Journal of Neuroscience Methods, 2000, 102, 2, 133

    CrossRef

  76. 76
    Chuang Chin Chiueh, Tsugunobu Andoh, Andrew Ryan Lai, Edgar Lai, Gopal Krishna, Neuroprotective strategies in parkinson’s disease: protection against progressive nigral damage induced by free radicals, Neurotoxicity Research, 2000, 2, 2-3, 293

    CrossRef

  77. 77
    D.C German, C.-L Liang, K.F Manaye, K Lane, P.K Sonsalla, Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons, Neuroscience, 2000, 101, 4, 1063

    CrossRef

  78. 78
    Gary W Miller, Raul R Gainetdinov, Allan I Levey, Marc G Caron, Dopamine transporters and neuronal injury, Trends in Pharmacological Sciences, 1999, 20, 10, 424

    CrossRef

  79. 79
    Gary W. Miller, Jeffrey D. Erickson, Jeffrey T. Perez, Shannon N. Penland, Deborah C. Mash, David B. Rye, Allan I. Levey, Immunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson's Disease, Experimental Neurology, 1999, 156, 1, 138

    CrossRef